权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

T32 Cincinnati Pediatric Clinical Pharmacology Training Program

T32 辛辛那提儿科临床药理学培训计划

基本信息

批准号：
10631893
负责人：
TRACY A GLAUSER
金额：
$ 16.11万
依托单位：
CINCINNATI CHILDRENS HOSP MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-05-16 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10631893
关键词：
Childhood Clinical Pharmacology Training Programs

项目摘要

PROJECT SUMMARY This is a competitive renewal application for the continuation of a highly collaborative and successful pediatric clinical pharmacology training program at Cincinnati Children's Hospital Medical Center and the University of Cincinnati. The program will train a new generation of pediatric investigators to assume leadership roles in the application of innovative, high impact quantitative clinical pharmacology approaches to improve the development, rational use and tailoring of new and existing drug therapies for neonates, infants, children, adolescents and young adults. The need for pediatric clinical pharmacology research and training has never been greater. The T32 Training Program in Pediatric Clinical Pharmacology at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and the University of Cincinnati, College of Medicine (UCCoM). The program outlined in this renewal application draws on strong leadership and a diverse group of well-established faculty mentors actively involved in subspecialty clinical pharmacology research, representing 18 divisions within the Department of Pediatrics, the Departments of Pharmacology & Systems Physiology and Biomedical Informatics at the UCCoM, and the James L. Winkle College of Pharmacy. The program has tremendous institutional support and takes advantage of broad areas of distinction and resources within a uniquely collaborative environment. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement as it: (1) has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; (2) involves the application and development of innovative quantitative methodologies such as PK/PD modeling and pharmacometrics, quantitative systems pharmacology modeling and simulation and model-informed clinical trial design; (3) is embedded in the institutional and UCCoM pharmacogenetic/genomics research and training endeavors through the Center for Pediatric Genomics; (4) is closely integrated with Bioinformatics and Health Services and Outcomes Research; and (5) can rely on over 10 years of a well-established curriculum after two funding cycles as a successful training program. The program provides a unique training experience to MDs, PharmDs, and PhDs to become the next generation of leaders whose work will advance pediatric clinical pharmacology and to have an extraordinary impact on pediatric therapeutics and health outcomes for children. The program has successfully opened new avenues to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics.

项目摘要这是一个有竞争力的续约申请，以继续高度合作和成功的儿科辛辛那提儿童医院医学中心和芝加哥大学的临床药理学培训项目辛辛那提。该计划将培训新一代儿科研究人员，以承担领导作用，应用创新的、高影响力的定量临床药理学方法来改善为新生儿、婴儿、儿童开发、合理使用和定制新的和现有的药物疗法，青少年和年轻人。儿科临床药理学研究和培训的需要从来没有更伟大。辛辛那提儿童医院儿科临床药理学T32培训项目医疗中心（CCHMC）是专门为满足这一关键需求而设计的。该计划是基于在临床药理学部，是儿科系和大学的联合单位的辛辛那提医学院（UCCoM）。在此更新申请中概述的计划借鉴了强大的领导层和一群积极参与亚专业临床的成熟的教师导师药理学研究，代表儿科系内的18个部门，药理学与系统生理学和生物医学信息学，以及詹姆斯L。温克尔药学院。该计划有巨大的机构支持，并利用广泛的领域在一个独特的协作环境中的区别和资源。T32培训计划是创新，并与计划公告中概述的目标保持一致，因为它：（1）专注于通过正在进行的研究，在多个不同儿科人群中进行早期和后期研究与所有主要儿科专科的合作;（2）涉及应用和开发创新的定量方法，如PK/PD建模和药物计量学，定量系统药理学建模和模拟以及模型知情的临床试验设计;（3）嵌入机构和UCCoM药物遗传学/基因组学研究和培训工作，通过中心，儿科基因组学;（4）与生物信息学和健康服务和成果研究紧密结合; 和（5）经过两个资助周期后，可以依靠超过10年的完善课程作为成功的培训计划。该计划提供了一个独特的培训经验，医学博士，药学博士，博士成为下一代领导人，他们的工作将推动儿科临床药理学，并有一个对儿科治疗和儿童健康结果的非凡影响。该计划成功地开辟了新的途径，以扩大人才库的年轻临床研究人员与职业兴趣，儿科治疗学

项目成果

期刊论文数量（39）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy.

DOI：
10.1002/jcph.1315
发表时间：
2019-03
期刊：
Journal of clinical pharmacology
影响因子：
2.9
作者：
Euteneuer JC;Kamatkar S;Fukuda T;Vinks AA;Akinbi HT
通讯作者：
Akinbi HT

Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.

HdxSim 的基本原理、开发和验证，这是一种临床决策支持工具，用于为患有镰状细胞性贫血的儿童提供基于模型的羟基脲精确剂量。

DOI：
10.1002/cpt.3119
发表时间：
2023
期刊：
Clinical pharmacology and therapeutics
影响因子：
6.7
作者：
Power-Hays,Alexandra;Dong,Min;Punt,Nieko;Mizuno,Tomoyuki;Smart,LukeR;Vinks,AlexanderA;Ware,RussellE
通讯作者：
Ware,RussellE

Validation of a pediatric population pharmacokinetic model for vancomycin.